Updated COVID ‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions
Authors' conclusion
We observed decreased odds of COVID-19-related hospitalizations among patients with autoimmune rheumatic conditions who received an updated COVID-19 or booster vaccine compared to those who received the initial series alone or were unvaccinated.
Study context
- Population
- Adults with autoimmune rheumatic conditions and incident COVID-19, December 2020–August 2024, N3C datamedian age 62 years
- Participants
- 60,980 adults
- Exposure
- COVID-19 vaccination status vs unvaccinated
- Updatedn = 6,336
- Outcome
- COVID-19-related hospitalization
Methodological detailsmixed-effects logistic regression, adjusted for demographics, clinical risk, social vulnerability and medications
- Mixed-effects logistic regression
- Adjusted for demographics, clinical risk, social vulnerability and medications
Main finding
As reported in the abstract
Each group vs unvaccinatedAdjusted odds ratio (95% CI)
Initial series
0.59(0.56–0.63)
Booster
0.29(0.27–0.31)
Updated
0.31(0.28–0.34)
Observational data: associations, not effects.
Further findings
| Outcome | Absolute risk reduction |
|---|---|
| COVID-19-related hospitalization, booster/updated vs initial series only | 5.6% |
Original publication
Updated COVID ‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions. Arthritis Rheumatol. Published 9 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →